Periprocedural anticoagulation for atrial fibrillation ablation

Area of Science:

• Cardiology
• Electrophysiology
• Thrombosis Research

Background:

• Catheter ablation for atrial fibrillation (AF) carries risks of left atrial (LA) thrombi and stroke.
• Optimal anticoagulation strategies during AF ablation remain undetermined.

Purpose of the Study:

• To evaluate the safety and efficacy of using warfarin and aspirin without low molecular weight heparin (LMWH) in patients undergoing AF ablation.

Main Methods:

• 207 patients underwent AF ablation with transesophageal echocardiography (TEE) to rule out LA clot.
• Heparin was used during the procedure, followed by aspirin pre-ablation and warfarin post-ablation.
• Warfarin and aspirin were continued for 6 weeks; LMWH was administered only if LA smoke was detected on TEE.

Main Results:

• Two patients experienced transient ischemic attacks (TIAs) post-ablation, both with subtherapeutic international normalized ratios (INRs).
• No other major thromboembolic events were reported in the study cohort.

Conclusions:

• Administering aspirin pre-ablation and warfarin post-ablation, without LMWH, is a safe anticoagulation method for AF ablation patients without LA thrombi or smoke.
• Meticulous intraprocedural anticoagulation is crucial for this strategy's success.